NYSE · ANRO
Healthcare · Biotechnology
$31.68
Down-$2.39 (-7.01%)
Updated Sep 11, 2026, 9:06 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ANRO closed at $31.68 after 20 trading sessions, down 1.92% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $33.71 | $34.20 | $31.35 | $31.68 | 790.03K |
| Sep 9, 2026 | $35.48 | $36.91 | $33.9067 | $34.07 | 556.88K |
| Sep 8, 2026 | $34.69 | $36.84 | $34.08 | $35.81 | 580.96K |
| Sep 4, 2026 | $36.175 | $36.9799 | $35.45 | $35.55 | 269.95K |
| Sep 3, 2026 | $36.84 | $37.36 | $35.91 | $36.40 | 324.66K |
| Sep 2, 2026 | $35.97 | $37.3899 | $35.22 | $36.64 | 432.78K |
| Sep 1, 2026 | $35.20 | $36.04 | $34.62 | $35.20 | 350.25K |
| Aug 31, 2026 | $34.89 | $35.83 | $33.98 | $35.38 | 764.12K |
| Aug 28, 2026 | $35.00 | $35.72 | $34.7301 | $35.13 | 246.76K |
| Aug 27, 2026 | $36.08 | $36.82 | $35.46 | $36.30 | 359.81K |
| Aug 26, 2026 | $35.80 | $36.86 | $34.87 | $36.53 | 282.85K |
| Aug 25, 2026 | $36.52 | $37.48 | $35.74 | $36.31 | 474.21K |
| Aug 24, 2026 | $33.96 | $36.99 | $33.5201 | $36.25 | 867.97K |
| Aug 21, 2026 | $34.44 | $35.29 | $33.66 | $34.28 | 291.17K |
| Aug 20, 2026 | $34.36 | $34.65 | $33.65 | $34.25 | 313.93K |
| Aug 19, 2026 | $35.00 | $35.41 | $33.805 | $34.89 | 335.73K |
| Aug 18, 2026 | $33.18 | $34.54 | $33.08 | $34.13 | 433.91K |
| Aug 17, 2026 | $32.15 | $34.35 | $31.08 | $33.60 | 863.68K |
| Aug 14, 2026 | $31.77 | $32.29 | $29.8808 | $32.14 | 874.49K |
| Aug 13, 2026 | $30.00 | $33.67 | $29.59 | $32.30 | 989.98K |
The latest Smart Investors Daily articles mentioning ANRO.
ANRO research
Company profile and research snapshot.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2026 | Wedbush | Neutral | — |
| Aug 13, 2026 | BTIG | Buy | — |
| May 18, 2026 | Baird | Outperform | — |
| May 14, 2026 | Wedbush | Neutral | — |
No generated briefing is available yet.
Yahoo · Aug 27, 2026
MOUNTAIN VIEW, Calif., August 27, 2026--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026.
Benzinga · Aug 27, 2026
Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief
Benzinga · Aug 17, 2026
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alto Neuroscience (NYSE:ANRO) with a Buy and raises the price target from $50 to $55.
Yahoo · Aug 16, 2026
Alto Neuroscience (ANRO) is back in focus after reporting second quarter 2026 results. The company reported a net loss of US$27.64 million and a basic loss per share from continuing operations of US$0.65. See our latest analysis for Alto Neuroscience. Alto Neuroscience’s latest quarterly loss lands against a backdrop of rapid share price gains, with a 90 day share price return of 47.43% and a year to date share price return of 93.73%, suggesting strong recent momentum. The 1 year total...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ANRO.
